WuXi Biologics (Cayman) Inc. (WXXWY)
| Market Cap | 11.93B |
| Revenue (ttm) | 2.56B |
| Net Income (ttm) | 459.79M |
| Shares Out | n/a |
| EPS (ttm) | 0.11 |
| PE Ratio | 25.95 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 708 |
| Average Volume | 60,590 |
| Open | 6.03 |
| Previous Close | 5.81 |
| Day's Range | 6.03 - 6.03 |
| 52-Week Range | 2.58 - 7.30 |
| Beta | 0.68 |
| RSI | 51.28 |
| Earnings Date | Mar 21, 2025 |
About WuXi Biologics
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufact... [Read more]
Financial Performance
In 2024, WuXi Biologics's revenue was 18.68 billion, an increase of 9.63% compared to the previous year's 17.03 billion. Earnings were 3.36 billion, a decrease of -1.28%.
Financial numbers in CNY Financial StatementsNews
WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future SHANGHAI , April 22, 20...
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou ...
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site | WXXWY Stock News
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors- Proprietary process innovation reduces protein cost by nearly 7...
WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards
SHANGHAI , April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received ...
Wuxi Biologics ADR reports FY results
WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025
Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million...
WuXi Biologics Celebrates Eighth Consecutive CDMO Leadership Award Win
WuXi Biologics Celebrates Eighth Consecutive CDMO Leadership Award Win
WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year
SHANGHAI , March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received ...
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year
Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) Contributing to the 2025 World Water Day campaign to ensure the availability of water and s...
WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
Ranking in top 1% of S&P Global CSA Score Inclusion in Global Yearbook for third consecutive year Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI , March 10, 2025 /PRNewswire...
WuXi Biologics Launches EffiX⢠Platform to Enhance Protein and DNA Production
WuXi Biologics Launches EffiX⢠Platform to Enhance Protein and DNA Production
WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system.
WuXi Biologics Successfully Passes Japan PMDA GMP Inspection
WuXi Biologics Successfully Passes Japan PMDA GMP Inspection
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
WUXI, China , Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has ...
WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year
Ranked among the top 1% of more than 150,000 companies across 185 countries Trusted by global partners for strong sustainability commitment Recognized as a leader in Green CRDMO, driving innovation fo...
WuXi Biologics Recognized as ESG Top-Rated Company by Morningstar Sustainalytics
WuXi Biologics Recognized as ESG Top-Rated Company by Morningstar Sustainalytics
WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year
Ranked among the top 1% of companies assessed in the pharmaceutical industry Recognized as a leader in Green CRDMO, driving innovation for a healthier future Committed to creating long-term value for ...
WuXi Biologics: Spotlight On Property Disposal And Operating Metrics (Rating Upgrade)
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million
WuXi Biologics' move to sell the facility could strengthen the company's cash flow and margins as it navigates global uncertainties.
WuXi Bio to Sell Vaccine Facility to Merck for $500 Million
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical t...
WuXi Biologics Announces Strategic Agreement with Candid Therapeutics
WuXi Biologics Announces Strategic Agreement with Candid Therapeutics
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and infla...
WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager
SHANGHAI and SAN DIEGO , Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a...
China’s WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom
US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation explicitly names WuXi.